Eltrombopag in the Treatment of Immune Thrombocytopenia: Two-Center Experience from Istanbul.

Autor: Dogan EE; Department of Hematology, Medical Science University Prof. Dr. Cemil Tascioglu City Hospital, Darulaceze Cad. No:27 Sisli, Istanbul, Turkey., Turan Erkek E; Department of Hematology, Medical Science University Kartal Lutfu Kirdar City Hospital, Istanbul, Turkey., Elverdi T; Department of Hematology, Istanbul University Cerrahpasa Faculty of Medicine, Istanbul, Turkey., Celik Kamaci S; Department of Internal Medicine, Medical Science University Prof. Dr. Cemil Tascioglu City Hospital, Istanbul, Turkey., Ciftci U; Department of Internal Medicine, Medical Science University Prof. Dr. Cemil Tascioglu City Hospital, Istanbul, Turkey., Demirel N; Department of Hematology, Medical Science University Prof. Dr. Cemil Tascioglu City Hospital, Darulaceze Cad. No:27 Sisli, Istanbul, Turkey., Aydin D; Department of Hematology, Medical Science University Prof. Dr. Cemil Tascioglu City Hospital, Darulaceze Cad. No:27 Sisli, Istanbul, Turkey., Eren R; Department of Hematology, Medical Science University Prof. Dr. Cemil Tascioglu City Hospital, Darulaceze Cad. No:27 Sisli, Istanbul, Turkey.
Jazyk: angličtina
Zdroj: Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion [Indian J Hematol Blood Transfus] 2022 Apr; Vol. 38 (2), pp. 327-332. Date of Electronic Publication: 2021 Jul 05.
DOI: 10.1007/s12288-021-01462-5
Abstrakt: Immune Thrombocytopenia (ITP) is a disease caused by autoantibodies forming against platelets and T cell dysregulation and is characterized by platelet count falling below 100 × 10 9 /L. Corticosteroids remain as the first-line of treatment, but in the light of recent developments, thrombopoietin receptor agonists are gradually replacing splenectomy in steroid-dependent or refractory patients. In this study, it was aimed to retrospectively evaluate the efficacy, safety and side-effect profile of eltrombopag treatment for chronic ITP. A total of 23 chronic ITP patients treated with eltrombopag from two health institutions in Istanbul were evaluated retrospectively. Overall response rate (partial or complete) was 87%, complete response rate was 78.3%, and the median time from treatment until reaching platelet counts above 50 × 10 9 /L was 14 days (min-max: 4-126). Treatment was discontinued in four patients due to persistent response, two of these were still fully responsive. During treatment, one patient developed basal cell carcinoma, and another developed chronic myelomonocytic leukemia. Although its long-term side effects are not yet known, eltrombopag is a very effective treatment option in ITP and may provide favorable outcomes in patients.
Competing Interests: Conflict of interestThe authors declare that they have no conflicts of interest.
(© Indian Society of Hematology and Blood Transfusion 2021.)
Databáze: MEDLINE
Externí odkaz: